| Description | The antibody CR3022-B6 is a human mAb specific for SARS-CoV-2 Spike S1 protein. It bound to soluble recombinant SARS-CoV-2 RBD with a KD of 290 nM. It was capable of neutralizing live SARS-CoV-2 virus with an IC50 of 4.4 µg/ml. It was further improved through affinity maturation by targeting all six CDRs for diversification using Kunkel mutagenesis and off-rate selections on phage using biotinylated SARS-CoV-2 RBD. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | SARS-CoV-2 |
| Epitope | The antibody binds to soluble recombinant SARS-CoV-2 RBD with high affinity. |
| Affinity | The binding affinity of CR3022-B6 was 290 nM for soluble recombinant SARS-CoV-2 RBD. |
| Isotype | IgG1 |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA, Neut |
| Application Notes | CR3022-B6 was capable of neutralizing live SARS-CoV-2 virus with an IC50 of 4.4 µg/ml. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Western Blot Protocol |
| Target | SARS-CoV-2 |
| Alternative Name | Severe acute respiratory syndrome coronavirus 2 |
| Research Area | Coronavirus Disease 2019 |
| Related Disease | Coronavirus Disease 2019 |
